Regulus Therapeutics Inc. (NASDAQ: RGLS)
$1.78
+0.0400 ( +2.30% ) 532.2K
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
Market Data
Open
$1.78
Previous close
$1.74
Volume
532.2K
Market cap
$116.53M
Day range
$1.70 - $1.81
52 week range
$1.08 - $3.79
SEC Fillings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 4 | Insider transactions | 1 | May 17, 2024 |
| 4 | Insider transactions | 1 | May 17, 2024 |
| 10-q | Quarterly Reports | 52 | May 09, 2024 |
| 8-k | 8K-related | 15 | May 09, 2024 |
| def | Proxies and info statements | 18 | Apr 19, 2024 |
| ars | Annual reports | 1 | Apr 19, 2024 |
| 10-k | Annual reports | 88 | Mar 21, 2024 |
| 8-k | 8K-related | 15 | Mar 21, 2024 |
| 4 | Insider transactions | 1 | Mar 15, 2024 |
| 8-k | 8K-related | 21 | Mar 14, 2024 |